Money
Filter News
Found 78,482 articles
-
Nyxoah Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
3/22/2023
Nyxoah SA, a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea, reported financial and operating results for the fourth quarter and full year 2022.
-
3SBio announces 2022 annual results, with revenue rising 7.5% year on year and normalized net profit attributable to parents jumping 25.2%
3/22/2023
Chinese leading biopharmaceutical company 3SBio announced its 2022 annual results.
-
Flare Therapeutics Announces Oversubscribed $123 Million Series B Financing
3/22/2023
Flare Therapeutics Inc. announced a $123 million Series B financing co-led by GordonMD® Global Investments LP and Pfizer Ventures, with participation from existing investors Boxer Capital, Casdin Capital, Eventide Asset Management, Invus Financial Advisors, Nextech Invest and Third Rock Ventures and new investors Agent Capital, Eli Lilly and Company, Memorial Sloan Kettering Cancer Center, Novartis, Pavilion Capital and ShangBay Capital.
-
Karuna Therapeutics Announces Pricing of Public Offering of Common Stock - March 22, 2023
3/22/2023
Karuna Therapeutics, Inc. announced the pricing of an underwritten public offering of 2,479,391 shares of its common stock at a public offering price of $161.33 per share.
-
Rakovina Therapeutics Receives Funding to Accelerate Development of Novel Cancer Therapies
3/22/2023
Rakovina Therapeutics Inc. (TSXV: RKV) (“the Company”), is pleased to announce that it is receiving advisory services and up to $122,865 in non-dilutive research and development funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP).
-
Scilex Holding Company Announces Financing of up to $25 Million to Enhance Commercialization of Three FDA Approved Non-Opioid Pain Management Products
3/21/2023
Scilex Holding Company announced that it has entered into a securities purchase agreement with YA II PN, Ltd., a Cayman Islands exempt limited partnership managed by Yorkville Advisors Global, LP (”Yorkville”), for the issuance and sale of unsecured convertible debentures in the principal amount of up to $25 million.
-
PREVISE CLOSES $3M SEED TO TACKLE EARLY CANCER DETECTION AND LAUNCHES COMPANY'S FIRST ESOPHAGEAL CANCER PROGNOSTIC TEST
3/21/2023
Previse, formerly known as Capsulomics, Inc., announced that the company has closed a $3M seed round and launched its first laboratory-developed test, Esopredict™.
-
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 21, 2023
3/21/2023
CTI BioPharma Corp. announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards to four new employees as equity inducement awards outside of the Company's Amended and Restated 2017 Equity Incentive Plan and material to the employees' acceptance of employment with the company.
-
Semler Scientific Reports Fourth Quarter and Full Year 2022 Financial Results
3/21/2023
Semler Scientific, Inc. reported financial results for the three months and year ended December 31, 2022.
-
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 21, 2023
3/21/2023
Avidity Biosciences, Inc. announced that on March 20, 2023, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 73,700 shares of its common stock and 36,850 restricted stock units to six new non-executive employees under the Avidity Biosciences, Inc.
-
X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides Corporate Update
3/21/2023
X4 Pharmaceuticals reported financial results for the fourth quarter and full year ended December 31, 2022 and highlighted key 2022 events and expected upcoming milestones.
-
Hyperfine, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results
3/21/2023
Hyperfine, Inc. announced fourth quarter and full year 2022 financial results and provided a business update.
-
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - March 21, 2023
3/21/2023
Avadel Pharmaceuticals plc announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to one new employee to purchase 15,000 ordinary shares under Avadel’s 2021 Inducement Plan.
-
Psychemedics Corporation Reports Fourth Quarter and Full Year 2022 Financial Results and Declares Quarterly Cash Dividend
3/21/2023
Psychemedics Corporation, the world’s largest provider of hair testing for drugs of abuse, announced fourth quarter and full year financial results for the period ended December 31, 2022.
-
Hemostemix Closes $762,400 of The Unit Private Placement
3/21/2023
Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce that it has closed its first tranche of its previously announced non-brokered private placement of units ("Units") for gross proceeds of $762,400 (the "Offering").
-
IntelGenx Announces Closing of Notes Offering - March 21, 2023
3/21/2023
IntelGenx Technologies Corp. announces the closing of an offering by way of private placement to certain investors in the United States of convertible notes due March 1, 2027 for aggregate gross proceeds of approximately US$760,000.
-
Albert Einstein College of Medicine and Montefiore Health System Awarded $30 Million from NIH to Support Its Institute for Clinical and Translational Research
3/21/2023
Albert Einstein College of Medicine and Montefiore Health System have received a seven-year, $30 million grant from the National Institutes of Health to continue support for the Harold and Muriel Block Institute for Clinical and Translational Research at Einstein and Montefiore.
-
Imunon Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4) - March 21, 2023
3/21/2023
Imunon, Inc. announced that the Compensation Committee of the Company’s Board of Directors approved the grant of inducement stock options to purchase a total of 5,250 shares of common stock and restricted stock grants totaling 1,100 shares of common stock as a material inducement to the employment to two individuals hired by Imunon during the first quarter of 2023.
-
In spite of a tumultuous economy, many life science companies have started the year off strong. With plans to expand its team and pipeline in the coming year, Takeda is one of them.
-
As demand for biotech talent increases, the need to offer competitive pay to the average employee puts financial pressure on companies to increase CEO pay as well.